VISIONEERING TECHNOLOGIES, INC. Visioneering Technologies, Inc. Stock
Equities
VTI
AU000000VTI2
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.16 AUD | -3.03% |
|
-8.57% | -36.00% |
| Sales 2022 | 7.28M 11.35M | Sales 2023 | 8.67M 13.51M | Capitalization | 8.79M 13.7M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -7.79M | Net income 2023 | -3M -4.68M | EV / Sales 2022 | 0.69 x |
| Net cash position 2022 | 3.49M 5.44M | Net cash position 2023 | 2.79M 4.34M | EV / Sales 2023 | 0.69 x |
| P/E ratio 2022 |
-1.18
x | P/E ratio 2023 |
-1.71
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 2.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Visioneering Technologies, Inc.
More press releases
| 1 day | -3.03% | ||
| 1 week | -8.57% | ||
| Current month | -11.11% | ||
| 1 month | -28.89% | ||
| 3 months | -28.89% | ||
| 6 months | -38.46% | ||
| Current year | -36.00% |
1 week
0.15
0.18
1 month
0.150.22
Current year
0.150.27
1 year
0.150.42
3 years
0.151.60
5 years
0.1510.50
10 years
0.1557.50
| Managers | Title | Age | Since |
|---|---|---|---|
Juan Aragon
CEO | Chief Executive Officer | - | 23-09-30 |
Brian D. Lane
DFI | Director of Finance/CFO | 62 | 18-12-09 |
Kuang-mon Tuan
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kathleen Miller
CHM | Chairman | 59 | 22-12-30 |
Allan Rubenstein
BRD | Director/Board Member | 79 | 22-06-28 |
| Director/Board Member | - | 20-11-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.16 | -3.03% | 138,058 |
| 24-04-18 | 0.165 | 0.00% | 90 |
| 24-04-17 | 0.165 | -5.71% | 83,434 |
| 24-04-15 | 0.175 | 0.00% | 4 |
| 24-04-12 | 0.175 | -2.78% | 12,264 |
Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT
More quotes
Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).
Calendar
2024-07-15
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.00% | 5.86M | |
| +10.42% | 39.04B | |
| -4.43% | 17.97B | |
| -25.69% | 2.12B | |
| -14.54% | 1.4B | |
| +14.75% | 1.12B | |
| -37.89% | 731M | |
| -38.39% | 724M | |
| -11.01% | 667M | |
| +15.96% | 491M |
- Stock Market
- Equities
- VTI Stock
